Source 1primary paper2026MED
Toolkit/Cry/Vip pyramiding
Cry/Vip pyramiding
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Countermeasures now integrate synergistic Cry/Vip pyramiding
Usefulness & Problems
Why this is useful
Cry/Vip pyramiding combines Cry and Vip toxin activities as a resistance-management countermeasure. The abstract presents it as a synergistic strategy.; resistance management against lepidopteran pests
Source:
Cry/Vip pyramiding combines Cry and Vip toxin activities as a resistance-management countermeasure. The abstract presents it as a synergistic strategy.
Source:
resistance management against lepidopteran pests
Problem solved
It is used to help counter field-evolved resistance that threatens long-term Bt efficacy.; countering field-evolved resistance to Bt Cry toxins
Source:
It is used to help counter field-evolved resistance that threatens long-term Bt efficacy.
Source:
countering field-evolved resistance to Bt Cry toxins
Problem links
countering field-evolved resistance to Bt Cry toxins
LiteratureIt is used to help counter field-evolved resistance that threatens long-term Bt efficacy.
Source:
It is used to help counter field-evolved resistance that threatens long-term Bt efficacy.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A composed arrangement of multiple parts that instantiates one or more mechanisms.
Mechanisms
synergistic multi-toxin pyramidingTarget processes
editingImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: multi component delivery burdenoperating role: regulatorswitch architecture: multi component
Implementation requires access to both Cry and Vip toxin components within a crop protection context.; requires combining Cry and Vip toxin activities
Uses more than one coordinated component. Independent follow-up evidence is still limited. Validation breadth across biological contexts is still narrow. Independent reuse still looks limited, so the evidence base may be fragile. Multi-component delivery and stoichiometry control can make deployment harder. No canonical validation observations are stored yet, so context-specific performance remains under-specified.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Next-generation countermeasures for Bt resistance include synergistic Cry/Vip pyramiding, CRISPR/Cas9-validated receptor knockouts revealing functional redundancy, Domain III chimerization, PACE, and AlphaFold3-guided rational redesign.
Countermeasures now integrate synergistic Cry/Vip pyramiding, CRISPR/Cas9-validated receptor knockouts revealing functional redundancy, Domain III chimerization (e.g., Cry1A.105), phage-assisted continuous evolution (PACE), and the emerging application of AlphaFold3 for structure-guided rational redesign of resistance-breaking variants.
Approval Evidence
1 source1 linked approval claimfirst-pass slug cry-vip-pyramiding
Countermeasures now integrate synergistic Cry/Vip pyramiding
Source:
engineering strategysupports
Next-generation countermeasures for Bt resistance include synergistic Cry/Vip pyramiding, CRISPR/Cas9-validated receptor knockouts revealing functional redundancy, Domain III chimerization, PACE, and AlphaFold3-guided rational redesign.
Countermeasures now integrate synergistic Cry/Vip pyramiding, CRISPR/Cas9-validated receptor knockouts revealing functional redundancy, Domain III chimerization (e.g., Cry1A.105), phage-assisted continuous evolution (PACE), and the emerging application of AlphaFold3 for structure-guided rational redesign of resistance-breaking variants.
Source:
Comparisons
Source-stated alternatives
The abstract contrasts this strategy with receptor knockout studies, Domain III chimerization, PACE, and AlphaFold3-guided redesign.
Source:
The abstract contrasts this strategy with receptor knockout studies, Domain III chimerization, PACE, and AlphaFold3-guided redesign.
Source-backed strengths
described as synergistic
Source:
described as synergistic
Compared with Domain III chimerization
The abstract contrasts this strategy with receptor knockout studies, Domain III chimerization, PACE, and AlphaFold3-guided redesign.
Shared frame: source-stated alternative in extracted literature
Strengths here: described as synergistic.
Source:
The abstract contrasts this strategy with receptor knockout studies, Domain III chimerization, PACE, and AlphaFold3-guided redesign.
Ranked Citations
- 1.